Correction to: CEST MRI provides amide/amine surrogate biomarkers for treatment‑naïve glioma sub‑typing.

MLA

Mancini, Laura, et al. “Correction to: CEST MRI Provides Amide/Amine Surrogate Biomarkers for Treatment‑naïve Glioma Sub‑typing.” European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 7, June 2022, p. 2454. EBSCOhost, https://doi.org/10.1007/s00259-022-05798-6.

APA

Mancini, L., Casagranda, S., Gautier, G., Peter, P., Lopez, B., Thorne, L., McEvoy, A., Miserocchi, A., Samandouras, G., Kitchen, N., Brandner, S., De Vita, E., Torrealdea, F., Rega, M., Schmitt, B., Liebig, P., Sanverdi, E., Golay, X., & Bisdas, S. (2022). Correction to: CEST MRI provides amide/amine surrogate biomarkers for treatment‑naïve glioma sub‑typing. European Journal of Nuclear Medicine and Molecular Imaging, 49(7), 2454. https://doi.org/10.1007/s00259-022-05798-6

Chicago

Mancini, Laura, Stefano Casagranda, Guillaume Gautier, Philippe Peter, Bruno Lopez, Lewis Thorne, Andrew McEvoy, et al. 2022. “Correction to: CEST MRI Provides Amide/Amine Surrogate Biomarkers for Treatment‑naïve Glioma Sub‑typing.” European Journal of Nuclear Medicine and Molecular Imaging 49 (7): 2454. doi:10.1007/s00259-022-05798-6.